KURA ONCOLOGY, INC. Payments to Acquire Short-term Investments
KURA ONCOLOGY, INC. (KURA) reported Payments to Acquire Short-term Investments of $191.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-12
- KURA ONCOLOGY, INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was $19.64M, a 82.87% decline year-over-year.
- KURA ONCOLOGY, INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $171.60M, a 36.14% decline year-over-year.
- KURA ONCOLOGY, INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $239.78M, a 0.34% decline year-over-year.
- KURA ONCOLOGY, INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $138.50M, a 124.37% increase year-over-year.
- KURA ONCOLOGY, INC. payments to acquire short-term investments for fiscal 2025 was $761.59M, a 15.56% increase from fiscal 2024.
- KURA ONCOLOGY, INC. payments to acquire short-term investments for fiscal 2024 was $659.05M, a 60.81% increase from fiscal 2023.
- KURA ONCOLOGY, INC. payments to acquire short-term investments for fiscal 2023 was $409.82M, a 51.42% increase from fiscal 2022.
- KURA ONCOLOGY, INC. payments to acquire short-term investments for fiscal 2022 was $270.65M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $191.24M 10-Q · filed 2026-08-12 | $431.01M derived: sum of 3 quarters · filed 2026-08-12 | $569.51M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $171.60M 10-Q · filed 2026-05-12 | $411.38M derived: sum of 2 quarters · filed 2026-05-12 | $549.88M derived: sum of 3 quarters · filed 2026-05-12 | $664.48M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $239.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $378.27M derived: sum of 2 quarters · filed 2026-03-05 | $492.87M derived: sum of 3 quarters · filed 2026-08-12 | $761.59M 10-K · filed 2026-03-05 |
| 2025-09-30 | $138.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $253.10M derived: sum of 2 quarters · filed 2026-08-12 | $521.81M 10-Q · filed 2025-11-04 | $762.40M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $114.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $383.31M 10-Q · filed 2026-08-12 | $623.90M derived: sum of 3 quarters · filed 2026-08-12 | $685.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $268.71M 10-Q · filed 2026-05-12 | $509.30M derived: sum of 2 quarters · filed 2026-05-12 | $571.03M derived: sum of 3 quarters · filed 2026-05-12 | $732.70M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $240.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $302.31M derived: sum of 2 quarters · filed 2026-03-05 | $463.99M derived: sum of 3 quarters · filed 2026-03-05 | $659.05M 10-K · filed 2026-03-05 |
| 2024-09-30 | $61.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $223.40M derived: sum of 2 quarters · filed 2025-11-04 | $418.46M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $161.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $356.74M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $195.06M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $409.82M 10-K · filed 2026-03-05 | |||
| 2022-12-31 | $270.65M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |